북미의 보툴리눔톡신(보톡스) 시장 예측(-2031년) - 지역별 분석 : 제품별, 용도별, 최종 사용자별

The North America botulinum toxin market was valued at US$ 4,801.29 million in 2023 and is expected to reach US$ 12,072.60 million by 2031; it is estimated to register a CAGR of 12.2% from 2023 to 2031.

Expanding Therapeutic Applications Fuel North America Botulinum Toxin Market

The botulinum toxins type A and B block vesicular acetylcholine released at neuromuscular and neurosecretory junctions, thereby delivering powerful therapeutic outcomes for treating patients requiring neurorehabilitation intervention. As per clinical reports, botulinum toxins have been proven to have therapeutic effects against headache, salivate, and hyperhidrosis, among others. Botulinum treatment can be adopted as an alternative to surgery. It appears to be a promising alternative to sphincterotomy in patients with chronic anal fissures. Patients suffering from a few autonomic disorders such as ptyalism or gustatory sweating, and hypersecretion of glands (a condition that often occurs after patients undergo surgeries involving parotid glands) respond well to botulinum toxins. Despite numerous advancements in the field of assisted reproductive technology, a significant number of patients still suffer from repeated implantation failure. Adequate endometrial growth plays a crucial role in embryo implantation and pregnancy continuation in an assisted reproductive procedure. For several years, botulinum toxins have been widely used in plastic and aesthetic surgeries; it has been revealed that botulinum toxins have a positive influence on the re-epithelialization of human keratinocytes and the angiogenesis of endothelial cells. Clinical results reveal that botulinum toxin administration facilitates the recovery of damaged structure and impaired function of the thin endometrium by increasing cellular proliferation and vessel formation, reducing collagen-accumulated lesions, and ultimately contributing to successful embryo implantation. Thus, the expanding therapeutic applications of botulinum toxins are likely to bring new botulinum toxins market trends in the coming years.

North America Botulinum Toxin Market Overview

The North America botulinum toxin market is segmented into the US, Canada, and Mexico. The market growth in North America can be mainly associated with the economically stable population and increasing numbers of nonsurgical or minimally invasive cosmetic procedures performed in the abovementioned countries. Reduction of facial wrinkles with botulinum toxin injections is the most performed cosmetic procedure in the US. It is one of the most common entry-level procedures for clinicians willing to incorporate aesthetic treatments into their practice. According to the International Society of Aesthetic Plastic Surgery (ISAPS), nearly 2.5 million botulinum toxin procedures were performed in the US in 2021. The treatment of frown lines and crow's feet approved by the US Food and Drug Administration- for cosmetic indications and horizontal forehead wrinkles provide predictable results, have few side effects, and high patient satisfaction. BOTOX Cosmetic/Vistabel by Allergan, Dysport/Azzalure by Galderma and Ipsen, Xeomin/Bocouture by Merz, and Jeuveau by Evolus (manufactured only by Daewoong for the US) are among the commercially available botulinum toxin products in the country. The US FDA has approved BOTOX Cosmetic for people from the age range of 18-65. According to the American Society for Aesthetic Plastic Surgery, botox injection is the fastest-growing procedure in the cosmetic industry. In August 2023, Daxxify (daxibotulinumtoxinA-lanm) was approved by the FDA as the first therapeutic indication to treat adult cervical dystonia. Cervical dystonia is characterized by uncontrollably occurring spasms or contractions in neck muscles, causing unusual movements, awkward posture, and head and neck pain. This condition affects approximately 60,000 Americans. The injection of botulinum toxin facilitates the relaxation of affected muscles in cervical dystonia patients, thereby reducing stiffness and spasms. However, the effect of the treatment slowly wears off, and thus, patients need frequent retreatments. Earlier, in July 2021, the FDA approved the label expansion of BOTOX Cosmetic of Allergan, an AbbVie company. Allergan has expanded BOTOX's applications to treat 8 new muscle conditions related to upper limb spasticity in adults.

North America Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)

North America Botulinum Toxin Market Segmentation

The North America botulinum toxin market is categorized into product, application, end user, and country.

Based on product, the North America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held the larger share of North America botulinum toxin market share in 2023.

In terms of application, the North America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held the larger share of North America botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow's feet, square jaw/ masseter, and others.

By end user, the North America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of North America botulinum toxin market in 2023.

Based on country, the North America botulinum toxin market is segmented into the US, Canada, and Mexico. The US dominated the North America botulinum toxin market share in 2023.

Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Aquavit, Revance Therapeutics Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd are some of the leading companies operating in the North America botulinum toxin market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. North America Botulinum Toxin Market - Key Market Dynamics

• 4.1 Market Drivers
  • 4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
  • 4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
• 4.2 Market Restraints
  • 4.2.1 Side Effects of Botulinum Toxin
• 4.3 Market Opportunities
  • 4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
• 4.4 Future Trends
  • 4.4.1 Expanding Therapeutic Applications
• 4.5 Impact of Drivers and Restraints:

5. Botulinum Toxin Market - North America Analysis

• 5.1 Overview
• 5.2 Botulinum Toxin Market Revenue (US$ Million), 2021-2031

6. North America Botulinum Toxin Market Analysis - by Product

• 6.1 Overview
• 6.2 Botulinum Toxin A
  • 6.2.1 Overview
  • 6.2.2 Botulinum Toxin A: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
• 6.3 Botulinum Toxin B
  • 6.3.1 Overview
  • 6.3.2 Botulinum Toxin B: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

7. North America Botulinum Toxin Market Analysis - by Application

• 7.1 Overview
• 7.2 Medical
  • 7.2.1 Overview
  • 7.2.2 Medical: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    • 7.2.2.1 North America Botulinum Toxin Market Breakdown, by Medical
• 7.3 Aesthetic
  • 7.3.1 Overview
  • 7.3.2 Aesthetic: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
    • 7.3.2.1 North America Botulinum Toxin Market Breakdown, by Aesthetic

8. North America Botulinum Toxin Market Analysis - by End User

• 8.1 Overview
• 8.2 Specialty and Dermatology Clinics
  • 8.2.1 Overview
  • 8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
• 8.3 Hospitals and Clinics
  • 8.3.1 Overview
  • 8.3.2 Hospitals and Clinics: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
• 8.4 Others
  • 8.4.1 Overview
  • 8.4.2 Others: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Botulinum Toxin Market - Country Analysis

• 9.1 North America: Botulinum Toxin Market
  • 9.1.1 North America: Botulinum Toxin Market - Revenue and Forecast Analysis - by Country
    • 9.1.1.1 United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.1.1.1.1 Overview
      • 9.1.1.1.2 United States: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.1.1.1.3 United States: Botulinum Toxin Market Breakdown, by Product
      • 9.1.1.1.4 United States: Botulinum Toxin Market Breakdown, by Application
      • 9.1.1.1.4.1 United States: Botulinum Toxin Market Breakdown, by Medical
      • 9.1.1.1.4.2 United States: Botulinum Toxin Market Breakdown, by Aesthetic
      • 9.1.1.1.5 United States: Botulinum Toxin Market Breakdown, by End User
    • 9.1.1.2 Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.1.1.2.1 Overview
      • 9.1.1.2.2 Canada: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.1.1.2.3 Canada: Botulinum Toxin Market Breakdown, by Product
      • 9.1.1.2.4 Canada: Botulinum Toxin Market Breakdown, by Application
      • 9.1.1.2.4.1 Canada: Botulinum Toxin Market Breakdown, by Medical
      • 9.1.1.2.4.2 Canada: Botulinum Toxin Market Breakdown, by Aesthetic
      • 9.1.1.2.5 Canada: Botulinum Toxin Market Breakdown, by End User
    • 9.1.1.3 Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.1.1.3.1 Overview
      • 9.1.1.3.2 Mexico: Botulinum Toxin Market - Revenue and Forecast to 2031 (US$ Million)
      • 9.1.1.3.3 Mexico: Botulinum Toxin Market Breakdown, by Product
      • 9.1.1.3.4 Mexico: Botulinum Toxin Market Breakdown, by Application
      • 9.1.1.3.4.1 Mexico: Botulinum Toxin Market Breakdown, by Medical
      • 9.1.1.3.4.2 Mexico: Botulinum Toxin Market Breakdown, by Aesthetic
      • 9.1.1.3.5 Mexico: Botulinum Toxin Market Breakdown, by End User

10. Company Profiles

• 10.1 Merz Pharma GmbH & Co KGaA
  • 10.1.1 Key Facts
  • 10.1.2 Business Description
  • 10.1.3 Products and Services
  • 10.1.4 Financial Overview
  • 10.1.5 SWOT Analysis
  • 10.1.6 Key Developments
• 10.2 AbbVie Inc
  • 10.2.1 Key Facts
  • 10.2.2 Business Description
  • 10.2.3 Products and Services
  • 10.2.4 Financial Overview
  • 10.2.5 SWOT Analysis
  • 10.2.6 Key Developments
• 10.3 Ipsen SA
  • 10.3.1 Key Facts
  • 10.3.2 Business Description
  • 10.3.3 Products and Services
  • 10.3.4 Financial Overview
  • 10.3.5 SWOT Analysis
  • 10.3.6 Key Developments
• 10.4 Evolus Inc
  • 10.4.1 Key Facts
  • 10.4.2 Business Description
  • 10.4.3 Products and Services
  • 10.4.4 Financial Overview
  • 10.4.5 SWOT Analysis
  • 10.4.6 Key Developments
• 10.5 Aquavit
  • 10.5.1 Key Facts
  • 10.5.2 Business Description
  • 10.5.3 Products and Services
  • 10.5.4 Financial Overview
  • 10.5.5 SWOT Analysis
  • 10.5.6 Key Developments
• 10.6 Revance Therapeutics Inc
  • 10.6.1 Key Facts
  • 10.6.2 Business Description
  • 10.6.3 Products and Services
  • 10.6.4 Financial Overview
  • 10.6.5 SWOT Analysis
  • 10.6.6 Key Developments
• 10.7 Medytox Inc
  • 10.7.1 Key Facts
  • 10.7.2 Business Description
  • 10.7.3 Products and Services
  • 10.7.4 Financial Overview
  • 10.7.5 SWOT Analysis
  • 10.7.6 Key Developments
• 10.8 Galderma SA
  • 10.8.1 Key Facts
  • 10.8.2 Business Description
  • 10.8.3 Products and Services
  • 10.8.4 Financial Overview
  • 10.8.5 SWOT Analysis
  • 10.8.6 Key Developments
• 10.9 Hugel Inc
  • 10.9.1 Key Facts
  • 10.9.2 Business Description
  • 10.9.3 Products and Services
  • 10.9.4 Financial Overview
  • 10.9.5 SWOT Analysis
  • 10.9.6 Key Developments
• 10.10 Lanzhou Institute of Biological Products Co Ltd
  • 10.10.1 Key Facts
  • 10.10.2 Business Description
  • 10.10.3 Products and Services
  • 10.10.4 Financial Overview
  • 10.10.5 SWOT Analysis
  • 10.10.6 Key Developments

11. Appendix

• 11.1 About The Insight Partners